Dogwood Therapeutics (NASDAQ:DWTX) Trading 1.7% Higher – Should You Buy?

Dogwood Therapeutics, Inc (NASDAQ:DWTX) traded up 1.7% on Friday . The company traded as high as $3.17 and last traded at $3.06. 49,806 shares changed hands during trading, an increase of 47% from the average session volume of 33,985 shares. The stock had previously closed at $3.01.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Dogwood Therapeutics in a research note on Monday, December 22nd. Wall Street Zen cut Dogwood Therapeutics to a “strong sell” rating in a research report on Saturday, December 13th. Finally, HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of Dogwood Therapeutics in a research report on Friday, February 20th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $12.00.

Dogwood Therapeutics Price Performance

The company has a market capitalization of $98.16 million, a price-to-earnings ratio of -0.12 and a beta of 1.90. The business’s 50-day moving average price is $3.01 and its two-hundred day moving average price is $4.73.

Hedge Funds Weigh In On Dogwood Therapeutics

An institutional investor recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP purchased a new position in Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned 0.51% of Dogwood Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 9.05% of the company’s stock.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.